Dr. Melisko on the MA.17R Study for ER+ Breast Cancer

Michelle E. Melisko, MD
Published: Thursday, Nov 09, 2017



Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), discusses the MA.17R study for patients with breast cancer.

The MA.17R study was a follow-up of the trial MA.17 where patients received 5 years of tamoxifen and were then randomized to receive placebo or an aromatase inhibitor (AI). More than 10 years ago, it was discovered that continuing an AI was beneficial, states Melisko.

MA.17R looked at the extension of an AI beyond 5 years, evaluating the added benefit of continuing an AI for 10 years compared to 5 years. Some women in the study received hormonal therapy for 15 years.

This trial met a statistically significant endpoint of reducing recurrences and improving disease-free survival. According to Melisko, this data was practice changing.
 
SELECTED
LANGUAGE


Michelle E. Melisko, MD, clinical professor of medicine, University of California, San Francisco (UCSF), discusses the MA.17R study for patients with breast cancer.

The MA.17R study was a follow-up of the trial MA.17 where patients received 5 years of tamoxifen and were then randomized to receive placebo or an aromatase inhibitor (AI). More than 10 years ago, it was discovered that continuing an AI was beneficial, states Melisko.

MA.17R looked at the extension of an AI beyond 5 years, evaluating the added benefit of continuing an AI for 10 years compared to 5 years. Some women in the study received hormonal therapy for 15 years.

This trial met a statistically significant endpoint of reducing recurrences and improving disease-free survival. According to Melisko, this data was practice changing.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x